DDInter255 DDInter1901
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
Busulfan {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Upadacitinib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nafcillin
Nafcillin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Busulfan {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Etoposide
Etoposide {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Busulfan {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Nafcillin
Nafcillin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Busulfan {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Nafcillin
Nafcillin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Busulfan {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Busulfan {u} (Compound) causes {v} (Side Effect) Inflammation
Inflammation {u} (Side Effect) is caused by {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Busulfan {u} (Compound) upregulates {v} (Gene) EPHA3
EPHA3 {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Busulfan {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Busulfan {u} (Compound) upregulates {v} (Gene) EPHA3
EPHA3 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Busulfan (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nafcillin (Compound) and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Busulfan (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Etoposide (Compound) and Etoposide may lead to a major life threatening interaction when taken with Upadacitinib
Busulfan (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Nafcillin (Compound) and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Busulfan (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Nafcillin (Compound) and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Busulfan (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Upadacitinib
Busulfan (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Upadacitinib
Busulfan (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is bound by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Busulfan (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Busulfan (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib